Biophytis Raises €2.6M for Clinical Programs
| Field | Detail |
|---|---|
| Company | Biophytis SA |
| Form Type | 6-K |
| Filed Date | Mar 26, 2025 |
| Risk Level | medium |
| Sentiment | bullish |
Sentiment: bullish
Topics: capital-raise, clinical-trial, biotech
TL;DR
Biophytis just closed a €2.6M capital raise to fund its Sarconeos trials.
AI Summary
On March 26, 2025, Biophytis S.A. announced the successful completion of a capital increase, raising €2.6 million. This funding will be used to advance its clinical programs, specifically the development of Sarconeos (BIO101) for COVID-19 and age-related muscle weakness.
Why It Matters
This capital infusion provides Biophytis with crucial funding to continue the development of its lead drug candidate, potentially impacting treatments for serious respiratory conditions.
Risk Assessment
Risk Level: medium — The company is still in clinical development, and the success of its drug candidates is not guaranteed, while the capital raise indicates a need for funding.
Key Numbers
- €2.6M — Capital Raised (Funds secured for clinical development)
Key Players & Entities
- Biophytis S.A. (company) — Registrant
- €2.6 million (dollar_amount) — Capital raised
- March 26, 2025 (date) — Date of announcement
- Sarconeos (BIO101) (drug) — Lead clinical program
- Stanislas Veillet (person) — Contact person
FAQ
What is the primary use of the €2.6 million raised by Biophytis?
The funds will be used to advance its clinical programs, including the development of Sarconeos (BIO101) for COVID-19 and age-related muscle weakness.
When was the capital increase announced?
The capital increase was announced on March 26, 2025.
What is the name of Biophytis's lead drug candidate mentioned in the filing?
The lead drug candidate mentioned is Sarconeos (BIO101).
What are the target indications for Sarconeos (BIO101)?
The target indications are COVID-19 and age-related muscle weakness.
What is the principal executive office address of Biophytis S.A.?
The principal executive office is located at Sorbonne University—BC 9, Bâtiment A 4ème étage 4 place Jussieu 75005 Paris, France.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 26, 2025 by Stanislas Veillet regarding Biophytis SA.